Wockhardt Sees Profit Surge Amid International Expansion

Wockhardt, a Mumbai-based drug firm, reported a consolidated profit of Rs 82 crore in Q2 2025, reversing a previous loss. Despite a dip in revenue, strategic expansion in the biotech diabetes sector and new markets contributed to growth. Share prices rose significantly.

Wockhardt, a pharmaceutical company headquartered in Mumbai, announced a consolidated profit after tax of Rs 82 crore for the second quarter of 2025, reversing a loss of Rs 16 crore from the same period last year.

Despite a revenue decrease to Rs 782 crore from Rs 818 crore, the company showed growth in key markets, with its India business growing by 3% and its UK operations by 4%.

The company's strategic initiatives, including expanded partnerships in the biotech diabetes sector and entry into markets like Russia and Malaysia, are propelling its international presence, as evidenced by a notable increase in share value by 10.43% on the BSE.